SEC Says There's 'No Dispute' Biotech Brass Broke Law

By Emilie Ruscoe (August 21, 2020, 9:22 PM EDT) -- The U.S. Securities and Exchange Commission on Friday sought partial judgments against the chief executive officer and chief financial officer of biotechnology company Osiris Therapeutics Inc., telling a Maryland federal judge that there was no good faith argument to be made that the men didn't violate federal securities law by scheming to cook the company's books....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!